Polymorphisms in CYP2D6 may predict methamphetamine related heart failure

Clinical Toxicology

Volumn 51, Issue 7, 2013, Pages 540-544

  Sutter, M E ^a   Gaedigk, A A ^b   Albertson, T E ^c   Southard, J ^c   Owen, K P ^a   Mills, L D ^a   Diercks, D B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Children's Mercy Hospital and Clinics   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Heart; Metabolic; Organ tissue specific

Indexed keywords

CYTOCHROME P450 2D6; METHAMPHETAMINE;

ADULT; ARTICLE; CARDIOMYOPATHY; CASE CONTROL STUDY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME POLYMORPHISM; ETHNICITY; FEMALE; GAS CHROMATOGRAPHY; GENDER; GENOTYPE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PILOT STUDY; PROSPECTIVE STUDY;

ADULT; AMPHETAMINE-RELATED DISORDERS; BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; CASE-CONTROL STUDIES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHI-SQUARE DISTRIBUTION; CYTOCHROME P-450 CYP2D6; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; GENETIC PREDISPOSITION TO DISEASE; HEART FAILURE; HUMANS; LOGISTIC MODELS; MALE; METHAMPHETAMINE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PHENOTYPE; PILOT PROJECTS; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SUBSTANCE ABUSE DETECTION;

EID: 84880817907     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2013.818684     Document Type: Article

References (21)

1. Green JS, O ' Brien TJ, Chiappinelli VA, Harralson AF . Pharmacogenomics instruction in US and Canadian medical schools: implications for personalized medicine . Pharmacogenomics 2010; 11 : 1331 - 1340
2. Hudson KL . Genomics, health care, and society . N Engl J Med 2011; 365 : 1033 - 1041
3. Marshall BD, Werb D . Health outcomes associated with methamphetamine use among young people: a systematic review . Addiction 2010; 105 : 991 - 1002
4. I to H, Y eo K K, W ijetunga M, S eto T B, T ay K, S chatz I J. A comparison of echocardiographic fi ndings in young adults with cardiomyopathy: with and without a history of methamphetamine abuse . Clin Cardiol 2009; 32 : E18 - E22
5. Willers ED, Newman JH . New risks for pulmonary hyper tension: need for a large epidemiologic study . Chest 2006; 130 : 1633 - 1635
6. S hetty V, M ooney L J, Z igler C M, B elin T R, M urphy D, R awson R . The relationship between methamphetamine use and increased dental disease . J Am Dent Assoc 2010; 141 : 307 - 318
7. Li L, Everhart T, Jacob Iii P, Jones R, Mendelson J . Stereoselectivity in the human metabolism of methamphetamine . Br J Clin Pharmacol 2010; 69 : 187 - 192
8. D iercks D B, F onarow G C, K irk J D, J ois-Bilowich P, H ollander J E, Weber JE, et al.; ADHERE Scientifi c Advisory Committee and Investigators . Illicit stimulant use in a United States heart failure population presenting to the emergency department (from the Acute Decompensated Heart Failure National Registry Emergency Module) . Am J Cardiol 2008 ; 102 : 1216 - 1219
9. K arch S B. T he unique histology of methamphetamine cardiomyopathy: a case report . Forensic Sci Int 2011; 212 : e1 - e4
10. Cherner M, Bousman C, Everall I, Barron D, Letendre S, Vaida F, et al.; HNRC Group . Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary fi ndings . J Int Neuropsychol Soc 2010; 16 : 890 - 901
11. Cherner M, Suarez P, Casey C, Deiss R, Letendre S, Marcotte T, et al.; HNRC Group . Methamphetamine use parameters do not predictneuropsychological impairment in currently abstinent dependent adults . Drug Alcohol Depend 2010; 106 : 154 - 163
12. Gaedigk A, Bradford LD, Alander SW, Leeder JS . CYP2D6 36 gene arrangements within the CYP2D6 locus: association of CYP2D6 36 with poor metabolizer status . Drug metabolism and disposition: the biological fate of chemicals 2006; 34 : 563 - 569
13. Gaedigk A, Ndjountche L, Divakaran K, Dianne Bradford L, Zineh I, Oberlander TF, et al . Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events . Clin Pharmacol Ther 2007; 81 : 242 - 251
14. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS . The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype . Clin Pharmacol Ther 2008; 83 : 234 - 242
15. Gaedigk A, Jaime LK, Bertino JS Jr, Berard A, Pratt VM, Bradfordand LD, Leeder JS . Identifi cation of novel CYP2D7-2D6 hybrids: non-functional and functional variants . Front Pharmacol 2010; 1 : 121
16. Richards JR, Bretz SW, Johnson EB, Turnipseed SD, Brofeldt BT, Derlet RW . Methamphetamine abuse and emergency department utilization . West J Med 1999; 170 : 198 - 202
17. Ingelman-Sundberg M . Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity . Pharmacogenomics J 2005; 5 : 6 - 13
18. Wilkinson GR . Drug metabolism and variability among patients in drug response . N Engl J Med 2005; 352 : 2211 - 2221
19. Srikanth S, Barua R, Ambrose J . Methamphetamine-associated acute left ventricular dysfunction: a variant of stress-induced cardiomyopathy . Cardiology 2008; 109: 188- 192
20. J acobs L J. R eversible dilated cardiomyopathy induced by methamphetamine . Clin Cardiol 1989; 12 : 725 - 727
21. Lopez JE, Yeo K, Caputo G, Buonocore M, Schaefer S . Recovery of methamphetamine associated cardiomyopathy predicted by late gadolinium enhanced cardiovascular magnetic resonance . J Cardiovasc Magn Reson 2009; 11 : 46